SavedAdd your journal

Journals / Türk Psikiyatri Dergisi / 2018 / Cilt: 29 - Sayı: 1

Neuropeptide Y Levels in Children and Adolescents with Attention Deficit Hyperactivity Disorder

Dikkat Eksikliği Hiperaktivite Bozukluğu Tanısı Konan Çocuk ve Ergenlerde Nöropeptit Y Düzeyleri

Özlem HEKİM BOZKURT
ESRA GÜNEY
Zeynep GÖKER
Gülser ŞENSES DİNÇ
Murat ALIŞIK
ÖZCAN EREL
Esra COP
ÖZDEN ŞÜKRAN ÜNERİ
Pages
31–35
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Future studies with homogeneous phenotypes and a larger sample population are needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in adolescence, however, the etiology has not been described.
📊
Key Findings & Data:The goal of this study was to evaluate NPY levels in children with ADHD and compare the findings to healthy controls.Methods: Forty-eight ADHD patients and 40 healthy controls were included in this study.
💡
Conclusion & Impact:Future studies with homogeneous phenotypes and a larger sample population are needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in adolescence, however, the etiology has not been described. Neuropeptide Y (NPY) is one potential factor that may be involved in the etiology of ADHD. The goal of this study was to evaluate NPY levels in children with ADHD and compare the findings to healthy controls.Methods: Forty-eight ADHD patients and 40 healthy controls were included in this study. The age range of ADHD patients was 6 to 16 years. All patients were diagnosed according to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). Results: The NPY levels of children with ADHD were compared to healthy controls but were not significantly different (t (86)= -0.887, p= 0.378). NPY levels were similar (F= 0.191, p= 0.826) between ADHD presentations, and included 8 children with predominantly hyperactive-impulsive type (14.3%), 14 children with predominantly inattentive type (30.4%), and 26 children with a combined type (55.4%). There was also no difference between ADHD patients using medical treatment, ADHD patients not using medical treatment, and control subjects in terms of NPY levels (F= 0.572, p= 0.566). There was a significant positive correlation between age and NPY levels in the ADHD group (r= 0.349, p= 0.015). Conclusion: This study demonstrated that the NPY levels of ADHD subjects were not different than those of controls. Future studies with homogeneous phenotypes and a larger sample population are needed.

Özet

Amaç: Dikkat eksikliği hiperaktivite bozukluğu (DEHB), çocukluk ça- ğının en yaygın psikiyatrik bozukluklarından biridir. DEHB'nin nedeni tam olarak bilinmemektedir. DEHB etiyolojisinde rol aldığı düşünülen etkenlerden biri Nöropeptit Y (NPY)'dir. Bu çalışmada, DEHB tanısı konan çocukların NPY düzeylerini değerlendirmek ve sağlıklı kontrol grubu ile karşılaştırmak amaçlanmıştır. Yöntem: 48 DEHB tanısı konmuş çocuk/ergen ve 40 sağlıklı kontrol bu çalışmaya dahil edildi. DEHB grubu yaş aralığı 6-16 idi. Tüm hastalara Amerikan Psikiyatri Birliği Ruhsal Bozuklukların Tanısal ve Sayımsal Elkitabı (DSM-5)'na göre tanı konuldu. Bulgular: DEHB tanısı konan çocuklar ile sağlıklı kontrollerin plazma NPY düzeyleri arasında istatistiksel olarak anlamlı fark yoktu (t (86) = -0,887, p = 0,378). Görünümlerine göre aşırı hareketlilik-dürtüselliğin baskın olduğu 8 (%14,3), dikkatsizliğin baskın olduğu 14 (%30,4) ve bileşik görünümü olan 26 çocukta (%55,4) NPY düzeyleri benzerdi (F= 0,191, p= 0,826). NPY düzeyleri açısından ilaç kullanan, kullanmayan ve kontrol grupları arasında da fark olmadığı belirlendi (F= 0,572, p= 0,566). DEHB grubunda yaş ve NPY düzeyleri arasında anlamlı pozitif korelasyon vardı (r= 0,349, p= 0,015). Sonuç: Bu çalışmada DEHB tanısı konan çocuklarda NPY düzeylerinin kontrol grubuna göre farklı olmadığı görüldü. Bu bulgu hakkında daha fazla bilgi edinilmesi için fenotip olarak homojen daha büyük örneklemlerde yapılacak çalışmalara ihtiyaç vardır.

🔖

Cite This Article

BOZKURT, Ö. H., GÜNEY, E., GÖKER, Z., DİNÇ, G. Ş., ALIŞIK, M., EREL, Ö., COP, E., ÜNERİ, Ö. Ş. (2018). Neuropeptide Y Levels in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Türk Psikiyatri Dergisi, Cilt: 29 - Sayı: 1, 31–35. https://ajindex.com/articles/87945

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Washington, DC. Bader R, Bettio A, Beck-Sickinger AG ve ark. (2001) Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection. J Mol Biol 305:307-29.
  2. Bari A, Dec A, Lee AW ve ark. (2014) Enhanced Inhibitory Control by Neuropeptide Y Y5 Receptor Blockade in Rats. Psychopharmacology 232:959-73.
  3. Cavadas C, Silva AP, Mosimann F ve ark. (2001) NPY regulates catecholamine secretion from human adrenal chromaffin cells. J Clin Endocrinol Metab 86:5956-63.
  4. Dumont Y, Martel JC, Fournier A ve ark. (1992) Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog Neurobiol 38:125-67.
  5. Dumont Y, Fournier A, St-Pierre S ve ark. (1996) Autoradiographic distribution of [125I]Leu31, [Pro34]PYY and [125I]PYY3-36 binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands. Synapse 22:139-58.
  6. Eaton K, Sallee FR, Sah R (2007) Relevance of neuropeptide Y (NPY) in psychiatry. Curr Top Med Chem 7:1645-59.
  7. Faraone SV, Bonvicini C, Scassellati C (2014) Biomarkers in the diagnosis of ADHD--promising directions. Curr Psychiatry Rep 16:497. Gackenheimer SL, Schober DA, Gehlert DR (2001) Characterization of neuropeptide Y Y1-like and Y2-like receptor subtypes in the mouse brain. Peptides 22:335-41.
  8. Gallagher M, Holland PC (1994) The amygdala complex: multiple roles in associative learning and attention. Proc Natl Acad Sci U S A 91:11771-6.
  9. Greco B, Carli M (2006) Reduced attention and increased impulsivity in mice lacking NPY-Y2 receptors: Relation to anxiolytic-like phenotype. Behav Brain Res 169:325-34.
  10. Gustafson EL, Smith KE, Durkin MM ve ark. (1997) Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system. Brain Res Mol Brain Res 46:223-35.
  11. Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatr Clin Neurosci 64:341-57.
  12. Heilig M, Zachrisson O, Thorsell A ve ark. (2004) Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 38:113-21.
  13. Karl T, Herzog H (2007) Behavioral profiling of NPY in aggression and neuropsychiatric diseases. Peptides 28:326-33.
  14. Kaye WH, Berrettini W, Gwirtsman H ve ark.